ES2121780T3 - Complejos de inclusion de 3-morfolino-sidnonimina o de sus sales o de su isomero tautomero, procedimiento de preparacion de tales complejos y composiciones farmaceuticas que los contienen. - Google Patents

Complejos de inclusion de 3-morfolino-sidnonimina o de sus sales o de su isomero tautomero, procedimiento de preparacion de tales complejos y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2121780T3
ES2121780T3 ES91907217T ES91907217T ES2121780T3 ES 2121780 T3 ES2121780 T3 ES 2121780T3 ES 91907217 T ES91907217 T ES 91907217T ES 91907217 T ES91907217 T ES 91907217T ES 2121780 T3 ES2121780 T3 ES 2121780T3
Authority
ES
Spain
Prior art keywords
complexes
salts
morfolino
inclusion
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907217T
Other languages
English (en)
Inventor
Maria Vikmon
Jozsef Szejtli
Lajos Szente
Jozsef Gaal
Istvan Hermecz
Agnes Horvath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therabel Industries SA
Original Assignee
Therabel Industries SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Industries SA filed Critical Therabel Industries SA
Application granted granted Critical
Publication of ES2121780T3 publication Critical patent/ES2121780T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPLEJOS DE INCLUSION DE 3-MORFOLINO -SIDNOMINIME O SUS SALES O SUS ISOMEROS TAUTOMER, PROCESO PARA LA PREPARACION DE LO ANTERIOR Y COMPOSICIONES FARMACOLOGICAS QUE CONTIENEN LO ANTERIOR. EL COMPLEJO DE INCLUSION DE 3-MORFOLINO-SIDNOMINIME O SUS SALES FORMADAS CON DERIVADOS DE LA CICLODEXTRIN ES PREPARADO POR (A) REACCION DEL 3-MORFOLINO-SIDNOMINIME O SUS SALES EN UN MEDIO ACUOSO CON DERIVADOS CICLODEBTRIN Y EL COMPLEJO ES AISLADO DE LA SOLUCION MEDIANTE DESHIDRATACION O (B) MILADO DE ALTA ENERGIA DEL 3-MOFOLINO-SIDNOMINIME O SUS SALES Y UN DERIVADO CICLODEXTRIN.
ES91907217T 1990-03-28 1991-03-28 Complejos de inclusion de 3-morfolino-sidnonimina o de sus sales o de su isomero tautomero, procedimiento de preparacion de tales complejos y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2121780T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU901869A HU212730B (en) 1990-03-28 1990-03-28 Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
PCT/HU1991/000013 WO1991014681A1 (en) 1990-03-28 1991-03-28 Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
ES2121780T3 true ES2121780T3 (es) 1998-12-16

Family

ID=10956597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907217T Expired - Lifetime ES2121780T3 (es) 1990-03-28 1991-03-28 Complejos de inclusion de 3-morfolino-sidnonimina o de sus sales o de su isomero tautomero, procedimiento de preparacion de tales complejos y composiciones farmaceuticas que los contienen.

Country Status (33)

Country Link
US (1) US5298496A (es)
EP (1) EP0478732B1 (es)
JP (1) JP2549961B2 (es)
KR (1) KR950004706B1 (es)
CN (1) CN1051081C (es)
AT (1) ATE170849T1 (es)
AU (1) AU635835B2 (es)
BG (1) BG61812B1 (es)
BR (1) BR9105137A (es)
CA (1) CA2054213C (es)
CZ (1) CZ285695B6 (es)
DE (1) DE69130146T2 (es)
DK (1) DK0478732T3 (es)
ES (1) ES2121780T3 (es)
FI (1) FI104882B (es)
GE (1) GEP19991743B (es)
HK (1) HK1011688A1 (es)
HR (1) HRP920560B1 (es)
HU (2) HU212730B (es)
LT (1) LT3257B (es)
LV (1) LV10087B (es)
MC (1) MC2186A1 (es)
MD (1) MD776C2 (es)
MW (1) MW6891A1 (es)
NO (1) NO303634B1 (es)
OA (1) OA09522A (es)
PL (1) PL165866B1 (es)
RO (1) RO109336B1 (es)
RU (1) RU2107695C1 (es)
SI (1) SI9110909B (es)
TJ (1) TJ189R3 (es)
UA (1) UA27242C2 (es)
WO (1) WO1991014681A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
HU218280B (en) 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
EP1280559B1 (en) * 2000-05-11 2006-03-08 Eastman Chemical Company Acylated cyclodextrin guest inclusion complexes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1496056A (fr) * 1964-06-08 1967-09-29 Takeda Chemical Industries Ltd Nouveaux composés chimiques du type sydnonimine
DE3221425A1 (de) * 1982-06-07 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim Hydrolyseempfindlichen wirkstoff enthaltende, lagerstabile tablette
DE3346638A1 (de) * 1983-12-23 1985-07-04 Cassella Ag, 6000 Frankfurt Photostabilisierung von molsidomin
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
DE3522191A1 (de) * 1985-06-21 1987-01-15 Cassella Ag Photostabilisierung von sydnoniminen
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
IT1204725B (it) * 1987-06-17 1989-03-10 Edmond Pharma Srl Complessi di inclusione del dipiridamolo con ciclodestrine
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
WO1991015346A1 (de) * 1990-04-06 1991-10-17 Gerhard Blatt Anlage zur behandlung von betonsteinen

Also Published As

Publication number Publication date
SI9110909B (sl) 1999-02-28
KR950004706B1 (ko) 1995-05-04
HRP920560B1 (en) 1999-12-31
NO303634B1 (no) 1998-08-10
CZ85291A3 (en) 1993-11-17
RU2107695C1 (ru) 1998-03-27
HU212730B (en) 1996-10-28
BR9105137A (pt) 1992-08-04
PL165866B1 (pl) 1995-02-28
HUT58110A (en) 1992-01-28
CN1051081C (zh) 2000-04-05
FI915570A0 (fi) 1991-11-26
LT3257B (en) 1995-05-25
CN1055928A (zh) 1991-11-06
DE69130146D1 (de) 1998-10-15
SI9110909A (sl) 1998-06-30
LV10087A (lv) 1994-05-10
MD940334A (en) 1996-10-31
EP0478732A1 (en) 1992-04-08
LV10087B (en) 1995-02-20
UA27242C2 (uk) 2000-08-15
HK1011688A1 (en) 1999-07-16
MC2186A1 (fr) 1992-09-16
EP0478732B1 (en) 1998-09-09
AU635835B2 (en) 1993-04-01
NO914650L (no) 1991-11-27
DE69130146T2 (de) 1999-04-01
JP2549961B2 (ja) 1996-10-30
TJ189R3 (en) 1998-10-28
PL293020A1 (en) 1992-12-28
LTIP387A (en) 1994-09-25
GEP19991743B (en) 1999-09-10
WO1991014681A1 (en) 1991-10-03
HU211648A9 (en) 1995-12-28
CA2054213C (en) 1998-12-01
MD776B2 (en) 1997-07-31
CZ285695B6 (cs) 1999-10-13
JPH04506221A (ja) 1992-10-29
MW6891A1 (en) 1993-07-14
HU901869D0 (en) 1990-07-28
KR920701183A (ko) 1992-08-11
MD776C2 (ro) 1998-05-31
ATE170849T1 (de) 1998-09-15
RO109336B1 (ro) 1995-01-30
FI104882B (fi) 2000-04-28
DK0478732T3 (da) 1999-06-07
CA2054213A1 (en) 1991-09-29
AU7549391A (en) 1991-10-21
US5298496A (en) 1994-03-29
HRP920560A2 (hr) 1994-04-30
OA09522A (en) 1992-11-15
BG61812B1 (bg) 1998-06-30
NO914650D0 (no) 1991-11-27

Similar Documents

Publication Publication Date Title
AR026052A1 (es) Derivados de purina
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
AR024345A1 (es) Derivados de purina
ES2012809B3 (es) Derivados del taxol, su preparacion y composiciones farmaceuticas que los contienen.
ES2076688T3 (es) Derivados de 2-hidroxi-2-feniletilamina utiles como agonistas de beta-3-adrenoceptores.
ES2011210T3 (es) Derivados de gem-difosfonato substituido, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CR6584A (es) Derivados de la purina
MX9400206A (es) Derivados de vinil-azaindol, proceso para su preparacion y composiciones farmaceuticas que los contienen.
AR245447A1 (es) Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas.
ES2084073T3 (es) Aclarados finales libres de cromo para metal fosfatado.
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
ES2121780T3 (es) Complejos de inclusion de 3-morfolino-sidnonimina o de sus sales o de su isomero tautomero, procedimiento de preparacion de tales complejos y composiciones farmaceuticas que los contienen.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2157315T3 (es) Derivados de 2-arilalquenil-azacicloalcanos ligandos a los receptores sigma, su procedimiento de preparacion y su aplicacion en terapeutica.
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
ES2059740T3 (es) Un metodo de fabricacion de un medicamento para inducir la contraccion uterina.
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9301404A (es) Derivados de 2-oxoquinolina, procedimiento para su preparacion, preparado farmaceutico que los contiene y procedimiento para la obtencion de tal preparado farmaceutico.
ES2059084T3 (es) Nuevos derivados de benzofurano, su procedimiento de preparacion, los nuevos productos intermedios y su aplicacion como plaguicidas.
AR014146A1 (es) Compuestos de triazina, su uso en terapia, composiciones farmaceuticas que los contienen, proceso para su manufactura e intermediarios de sintesis
ES2036137B1 (es) Procedimiento para la preparacion de la nueva 1-(3-clorofenil)-4-hidroximetil-7,8-dimetoxi-5h-2,3-benzodiacepina y de sus sales de adicion acida.
ES2090320T3 (es) Complejos de inclusion de n-etoxicarbonil-3-morfolino-sidnonimina o de sus sales formados con derivados de ciclodextrina, preparacion de los mismos y composiciones farmaceuticas que las contienen.
AR006675A1 (es) 4-benzoilisotiazoles herbicidas, procedimiento para obtenerlas, las composiciones herbicidas que las contienen y el procedimiento de aplicacionde dichos compuestos.
YU47914B (sh) Derivati 9-alfa-hidroksi-3-okso-4,24(25)-stigmastadien-26-ske kiseline i postupak za dobivanje istih

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 478732

Country of ref document: ES